You are here

Exparel (Bupivacaine)-Based Regimen Reduces Hospital Cost of Care Versus Standard Opioid-Based Treatment

Phase IV data show reductions in opioid consumption, total cost, and length of stay (Nov. 20)

Results from the first IMPROVE study to complete its prospective phase IV clinical program have been published in the online edition of the Journal of Pain Research.

The IMPROVE studies compared the differences in opioid use, total hospital cost, and length of stay (LOS) between patients receiving Exparel (bupivacaine liposome injectable suspension, Pacira Pharmaceuticals) as the foundation of an opioid-sparing multimodal regimen versus a standard opioid-based postsurgical pain-management regimen.

Compared with patients undergoing open colectomy in the standard opioid-based treatment arm, patients undergoing the same procedure and receiving an Exparel-based multimodal regimen had:

  • A 2.9-day reduction in median LOS (4.9 days in the hospital vs 2.0 days in the hospital, respectively; P = 0.004)
  • A $3,084 reduction in mean total hospital cost ($11,850 vs $8,766, respectively; P = 0.027)
  • A 58-mg reduction in mean opioid consumption (115 mg vs 57 mg, respectively; P = 0.025)

Eighteen patients were enrolled in the opioid-based group, and 21 patients were enrolled in the Exparel-based multimodal regimen group.

Exparel (bupivacaine liposome injectable suspension) is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The product combines bupivacaine with DepoFoam — a product-delivery technology that delivers bupivacaine over time, providing analgesia with reduced opioid requirements for up to 72 hours.

Source: Pacira Pharmaceuticals; November 20, 2012.

Recent Headlines

Almost 64% of Patients Showed Decreased Hemoglobin A1c Levels
Lifesaving Life Foam for Battlefield, Terrorist Attacks, Trauma
Cell Reprogramming Process May Benefit Patients Prone to Severe Hypoglycemia
Beagles Beat Out Advanced Technology
Over Half of Patients Had Reduced Pain Levels of 30% or More
Spina Bifida, Cleft Lip Among Defects Caused by Antiepilectics
Study Data Indicate Drug May Provide Complete Remission in PV
Teplizumab Slows Progression to Disease by at Least Two 2 Years
Over 25% of Study Patients Showed 6–12 Months Remission